Drug Trial Radar · NCT02601209
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Last checked: Nov 20, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
151
Actual
Start
Nov 30, 2015
Primary completion
Dec 7, 2018
Study completion Jul 11, 2022
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions
- High Grade Sarcoma
- Metastatic Leiomyosarcoma
- Metastatic Malignant Peripheral Nerve Sheath Tumor
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Metastatic Unresectable Sarcoma
- Myxofibrosarcoma
- Recurrent Leiomyosarcoma
- Recurrent Malignant Peripheral Nerve Sheath Tumor
- Recurrent Synovial Sarcoma
- Recurrent Undifferentiated Pleomorphic Sarcoma
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
- Unresectable Leiomyosarcoma
Interventions
PazopanibDrug
Given PO
Pazopanib HydrochlorideDrug
Given PO
SapanisertibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)Time frame: 28 days
- Progression-free Survival (PFS) (Phase II Analysis Group 2 - Initial Treatment Period)Time frame: Up to 2 years
Locations
460 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Eden Hospital Medical Center
Castro Valley, California
Sutter Davis Hospital
Davis, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Los Angeles County-USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Memorial Medical Center
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California
Sutter Cancer Research Consortium
Novato, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Keck Medical Center of USC Pasadena
Pasadena, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Sutter Medical Center Sacramento
Sacramento, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California
Sutter Pacific Medical Foundation
Santa Rosa, California
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California
Sutter Solano Medical Center/Cancer Center
Vallejo, California
Showing 40 of 460 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.